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Abstract 
Background: The gonadotropin-releasing hormone (GnRH) analog buserelin causes enteric neuronal loss. Acute 
stress or injection of corticotropin-releasing factor (CRF) affects motility, secretion, and barrier function of the gastro-
intestinal tract. The aim of the study was to characterize the CRF immunoreactivity in enteric neurons after buserelin 
treatment, and to evaluate possible effects of enteric neuropathy on gut microbiota, intestinal permeability, and stress 
response behavior.
Results: Sixty rats were given buserelin (20 μg) or saline subcutaneously for 5 days, repeated four times with 3 weeks 
in-between. At the study end, enteric neuronal density, enteric expression of CRF, gut microbial composition, and 
plasma levels of adrenocorticotropic hormone (ACTH) and CRF were analyzed. Intestinal permeability was examined 
in Ussing chambers and the reaction to stressful events was measured by behavior tests. Buserelin treatment reduced 
the number of neurons along the entire gastrointestinal tract, with increased relative numbers of CRF-immunoreac-
tive submucosal and myenteric neurons in colon (p < 0.05 and p < 0.01, respectively). The overall microbial diversity 
and relative abundance did not differ between groups, but Enterobacteriaceae was decreased in colon in buserelin-
treated rats (p = 0.020). Basal intestinal permeability did not differ between groups, whereas carbachol stimulation 
increased ileum permeability in controls (p < 0.05), but not in buserelin-treated rats. Buserelin did not affect stress 
behavior.
Conclusions: Although buserelin treatment leads to enteric neuronal loss along the gastrointestinal tract with an 
increased percentage of CRF-immunoreactive neurons in colon, the physiology is well preserved, with modest effects 
on colon microbiota and absence of carbachol-induced permeability in ileum as the only observed changes.
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Background
Gonadotropin-releasing hormone (GnRH) stimulates 
secretion of follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH) from the anterior pituitary, 
with subsequent secretion of steroid hormones from the 
gonads [1]. Studies indicate a role for the reproductive 
peptide hormones also in the gastrointestinal (GI) tract, 
since GnRH immunoreactivity is found in human enteric 
neurons [2, 3], and LH receptors are expressed in both 
human and rat myenteric neurons [4–6]. Some women 
develop severe dysmotility or abdominal pain after treat-
ment with GnRH analogs [2, 3, 7]. In rat, around 50 % of 
enteric neurons throughout the GI tract were lost after 
four treatment sessions with the GnRH analog buserelin, 
whereas morphological measurements showed normal 
histology in mucosa, submucosa, and muscle layers [5]. 
Still, the GI function regarding transit time and nutrient 
absorption was well preserved [8]. If translated into the 
clinical setting, it may suggest that patients with diffuse 
GI complaints can suffer from mild to moderate enteric 
neuropathy despite normal findings in standardized clini-
cal examinations.
Patients with dysmotility and GI symptoms show 
comorbidity with affective disorders, and their symptoms 
are influenced by psychological stress [9]. Corticotropin-
releasing factor (CRF) is a non-selective ligand to CRF 
receptor 1 and 2, although preferring CRF receptor 1, and 
is the principal regulator of pituitary adrenocorticotropic 
hormone (ACTH) and adrenal glucocorticoid secretion 
in response to stressful stimuli [10]. Elevated central 
CRF levels are involved in the etiology of stress-related 
psychiatric, physiological, and behavioral disorders [11]. 
Both experimental trials on animals, and clinical studies 
on man, demonstrate that CRF is implicated in anxiety 
and depression [12, 13]. CRF and CRF receptor 1 are to a 
great extent present in the enteric nervous system (ENS), 
where CRF is expressed in vasoactive intestinal peptide-
immunoreactive (VIP-IR) neurons [14–17]. Central or 
peripheral administration of CRF and endogenously 
stress-induced CRF release affect motility, secretion, 
inflammation, and permeability of the GI tract, and CRF 
added in cell cultures reverse the neuroprotective effects 
evoked by VIP, whereas administration of CRF antago-
nists alleviate the effects [10, 14–17]. However, the effect 
of intestinal CRF on stress behavior and gut function has 
not been studied.
Stress induces increased permeability of the GI mucosa, 
thereafter bacteria and luminal factors may cross the epi-
thelial barrier and activate a mucosal immune response. 
This response may in turn alter the microbiome compo-
sition and enhance the hypothalamic–pituitary–adrenal 
(HPA) drive [18]. The gut microbiota release transmit-
ter-like agents, which communicate with the ENS, and 
lipopolysaccharides (LPS), which affect the enteric neu-
rons via toll-like receptor-4 (TLR-4) [19]. Gut microbiota 
may influence the development of psychiatric disorders, 
since antibodies against LPS from commensal gut micro-
biota have been found in patients with depression or 
chronic fatigue syndrome [19]. Thus, both CRF and gut 
microbiota could play important roles in the develop-
ment of depression and anxiogenic behaviors.
Since buserelin treatment in man may cause severe GI 
side effects [2, 3, 7], there is a need to further characterize 
the rat model of buserelin-induced enteric neuropathy. 
Furthermore, functional consequences of enteric neurop-
athy must be studied in a rat model, to learn how to find 
and diagnose corresponding damage in patients with dif-
fuse GI dysfunction. The aims of the present study were 
thus to characterize CRF immunoreactivity in enteric 
neurons in the experimental rat model of repeated treat-
ment with the GnRH analog buserelin, and to evaluate 
possible effects evoked by enteric neuropathy on gut 




All animals exhibited normal activity and looked healthy 
in gross observation throughout the study period, why 
all individuals were included in the study. At the end 
of the second and third treatment period (weeks 5 and 
9), buserelin-treated rats showed a transient increase in 
body weight compared with control rats, with no differ-
ence in body weight gain between the two groups at sac-
rifice (Fig. 1). At week 5, the weight gain was 2.3 ± 0.8 % 
for controls and 5.4  ±  0.8  % for buserelin-treated rats 
(p  <  0.01). At week 9, the weight gain was 2.5 ±  0.6  % 
and 5.7  ±  0.5  % for controls and buserelin-treated, 
respectively (p < 0.001). At autopsy, the visceral organs 
were inspected and no lesions or abnormalities were 
identified.
Plasma analyses
Buserelin treatment (B) did not affect the plasma levels of 
ACTH compared with controls (C) (C = 693 (597–757) 
pg/ml, B = 694 (456–780) pg/ml). CRF levels in plasma 
were below detectable values in all rats (<0.039 ng/ml).
Neuronal survival
Submucosal and myenteric neurons stained well in all 
rats, irrespective of treatment.
After buserelin treatment, the absolute numbers of 
submucosal neurons were reduced in ileum and colon, 
but not in fundus (Fig. 2), whereas the numbers of myen-
teric neurons were reduced in fundus, ileum, and colon 
(Fig. 2).
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CRF‑immunoreactive neurons
In the fundic part of the stomach, no CRF-IR submucosal 
neurons were found, whereas a few short fibers were 
found innervating the mucosa, submucosa, submucosal 
ganglia, and blood vessel, in both controls and busere-
lin-treated rats. Around 1–2 % of the myenteric neurons 
were IR to CRF. Very few fibers innervating the muscle 
layers and the myenteric ganglia were identified in both 
groups.
In ileum, 8  % of the submucosal neurons were IR to 
CRF in controls compared with 13  % in the buserelin-
treated group (p  =  0.110). Of the myenteric neurons, 
there was a tendency to increased relative number of 
CRF-IR neurons in buserelin-treated rats (8 %) compared 
with controls (5  %) (p  =  0.076). Moderate numbers of 
CRF-IR fibers were seen in the mucosa, submucosal and 
myenteric ganglia, and around blood vessels, whereas a 
few of these fibers were seen in the submucosa and mus-
cle layers in both controls and buserelin-treated rats.
In colon, numerous CRF-IR fibers were present. Mod-
erate numbers of CRF-fibers were found in the submu-
cosal and myenteric ganglia, whereas few of these fibers 
were found in the submucosa, muscle layers, and around 
blood vessels in both groups of rats (Fig. 3a–b). The rela-
tive numbers of CRF-IR neurons in submucosal ganglia 
were 10 % in controls and 21 % in buserelin-treated rats 
(p < 0.05) (Fig. 3c–h, o). Seven percent of the myenteric 
neurons were CRF-IR in controls, which increased to 
19  % after buserelin treatment (p  <  0.01) (Fig.  3i–n, o). 
The absolute number of CRF-IR submucosal neurons/
mm ganglia in the colon were equal between controls 
Fig. 1 Body weight over time studied on rats treated with one 
to four sessions with saline (C, unfilled circle) or buserelin (B, filled 
circle). One session consists of 5 days of treatment, with one daily 
subcutaneous injection of saline or buserelin, followed by 3 weeks 
of recovery. All rats were healthy and gained weight throughout 
the experimentation. At the end of the second and third treatments 
(weeks 5 and 9), buserelin-treated rats showed a transient increase 
in weight compared with saline-treated rats. Results are presented 
as means and standard error of the mean (SEM) and analyzed by 
Student’s t test, C = 8–24 and B = 12–36. Statistical significance is 
indicated by **p < 0.01 and ***p < 0.001
Fig. 2 Numbers of neurons in submucosal (SG) and myenteric ganglia (MG) per mm length in fundus, ileum, and colon from rats treated with four 
sessions of saline (controls, C) or buserelin (B). Rats were euthanized 2 weeks after the fourth treatment session. Neuronal counting was performed 
on longitudinally cut, whole-wall sections. Rats subjected to four sessions of buserelin treatment showed decreased numbers of submucosal 
neurons in ileum (p < 0.05) and colon (p < 0.05), and myenteric neurons in fundus (p < 0.05), ileum (p < 0.01), and colon (p < 0.01), compared with 
controls. C = 7 rats and B = 11 rats. Results are presented as medians and interquartile ranges and were analyzed by the Mann–Whitney U-test. 
Statistical significance is indicated by *p < 0.05 and **p < 0.01
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and buserelin-treated rats, whereas the absolute number 
of CRF-IR myenteric neurons/mm ganglia was increased 
after buserelin treatment (Additional file 1: Figure S1).
NOS‑immunoreactive neurons in colon
The relative numbers of nitric oxide synthase (NOS)-IR 
neurons were 30  % in submucosal ganglia and 33  % in 
myenteric ganglia in both controls and buserelin-treated 
rats. NOS-IR nerve fibers were abundant in the circular 
muscle layer and myenteric ganglia. A moderate number 
of NOS-IR nerve fibers was seen in the submucosal 
ganglia, whereas few NOS-IR nerve fibers were seen in 
the mucosa, submucosa, and longitudinal muscle layer. 
NOS-IR nerve fibers were rarely found around blood ves-
sels. Buserelin treatment did not affect the distribution or 
staining intensity of NOS-IR neurons.
VIP‑immunoreactive neurons in colon
The relative numbers of VIP-IR neurons were high in 
submucosal ganglia (24 %) and low in myenteric ganglia 
Fig. 3 Cryo sections of colon from rats treated with four sessions of saline (controls, C) in the left panel or buserelin (B) in the right panel. Double-
immunostaining with human neuronal protein (Hu; green) and corticotropin-releasing factor (CRF; red). Micrographs a and b show intense 
CRF-immunostaining of fibers in the colon mucosa and submucosa. Micrographs c–h of submucosal ganglia (SG) are visualizing HuC/D-immuno-
reactive (IR) neurons (c, f) also IR to CRF (d, g). Micrographs c and d are merged in e, and micrographs f and g are merged in h. Micrographs i–n of 
myenteric ganglia (MG) are visualizing HuC/D-IR neurons (i, l) also IR to CRF (j, m). Micrographs i and j are merged in k, and micrographs l and m 
are merged in n. In micrograph o, the relative numbers of CRF-IR neurons in SG and MG of colon are presented. The percentage of CRF-IR neurons 
of the neurons IR to nitric oxide synthase (NOS, p) and vasoactive intestinal peptide (VIP, q) is presented. Four sessions of buserelin treatment 
increased the expression of submucosal NOS-IR neurons also showing CRF immunoreactivity (p < 0.05) (p), and there was a trend to increased 
numbers of myenteric NOS- and VIP-IR neurons also IR to CRF, compared with controls (both, p = 0.070) (p, q). C = 5 rats and B = 11 rats. Results are 
presented as individual values and medians and were analyzed by the Mann–Whitney U-test. Statistical significance is indicated by *p < 0.05 and 
**p < 0.01
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(1  %) in both groups. VIP-IR nerve fibers were abun-
dant in the mucosa, submucosa, and submucosal ganglia, 
moderate in numbers in the circular muscle layer and 
myenteric ganglia, and few in the longitudinal muscle 
layer. VIP-IR nerve fibers were detected around the blood 
vessels. Buserelin treatment did not affect the frequency 
of VIP-IR nerve fibers in the various layers.
Co‑expression of neuropeptides in colon
Four sessions of buserelin treatment increased the rela-
tive number of submucosal NOS-IR neurons also IR to 
CRF (Fig. 3p), and there was a trend to increased relative 
numbers of myenteric NOS-IR neurons also IR to CRF, 
and myenteric VIP-IR neurons also IR to CRF, compared 
with controls (both, p = 0.070) (Fig. 3p, q).
Gut microbial composition
Diversity of the gut bacterial flora
The diversity of the dominating taxa of the gut micro-
biota and diversity indices did not differ between con-
trol rats and buserelin-treated rats (Additional file  2: 
Table  S2). The overall gut microbial community struc-
ture was relatively similar, since no significant differences 
were observed between the groups when both richness 
and evenness were considered.
Firmicutes and Bacteroidetes were the two most 
dominant phyla in both controls and buserelin-treated 
rats, with no significant differences regarding the rela-
tive abundance of any phyla or families between groups 
(Fig. 4a).
Quantification of the gut bacterial flora
In ileum and colon, the total amount of bacteria and the 
amount of bacteria from the C. leptum group did not dif-
fer between the two treatments (Fig. 4b, c). The amount 
of Enterobacteriaceae was lower in colonic tissue of rats 
treated with buserelin compared with the control group 
(p < 0.05) (Fig. 4c), but significant differences could not 
be observed in ileum (Fig. 4b). Bacteria from the B. fra-
gilis group were not detected in any of the samples in the 
present study.
Intestinal permeability
During basal conditions, the intestinal permeability of 
mannitol, fluorescein isothiocyanate (FITC)-dextran, 
and bovine serum albumin (BSA) in ileum and colon was 
similar in buserelin-treated rats and control rats (Fig. 5). 
When stimulating the ileum with carbachol, the perme-
ability of mannitol, FITC-dextran, and BSA (at the latest 
time-point) increased in control rats (Fig. 5C). In busere-
lin-treated rats, no increase in permeability due to carba-
chol stimulation could be detected (Fig. 5B).
Stress behavior
In the elevated plus maze test (EPMT), the total num-
bers of entries, or entries into closed or open arms, did 
not differ between controls and buserelin-treated rats 
(Fig.  6a). Neither did the percentage of open or closed 
arm entries differ between the groups (data not shown). 
The total time spent into closed, open arms or the center 
platform did not differ between groups (Fig.  6b). There 
was no difference in how much time controls and buser-
elin-treated rats spent in the outer parts of the open 
arms (C = 72 (56–124) s, B = 76 (0–104) s). Neither was 
there any difference in how many times the rats entered 
the outer parts of the open arms (data not shown). Open 
arm head dips or protected arm head dips did not differ 
between the groups (data not shown). All parameters are 
presented for the entire 0–10-min period studied. When 
the data were analyzed in periods of 0–5 and 5–10 min, 
the results did not differ from the presented results (data 
not shown).
In the forced swimming test (FST), there was no statis-
tical significant difference in the time of struggling, swim-
ming or floating between controls and buserelin-treated 
rats (Fig.  7). The numbers of diving were recorded, but 
no difference between the groups was detected. These 
parameters were analyzed and presented for the entire 
0–10-min period studied. When the data were analyzed 
in periods of 0–5 min and 5–10 min, the results did not 
differ from the presented results (data not shown).
Discussion
The main findings in the present study of a rat model 
with buserelin-induced enteric neuropathy were that 
the gut microbiota composition, intestinal permeabil-
ity, and stress behavior responses are well preserved 
despite a neuronal loss of up to 50 % with imbalance in 
the CRF immunoreactivity. In colon, buserelin treat-
ment increased the relative numbers of submucosal and 
myenteric CRF-IR neurons, increased the relative num-
ber of NOS-IR submucosal neurons also IR to CRF, and 
tended to increase both the percentage of NOS- and 
VIP-IR myenteric neurons also IR to CRF. As buserelin 
did not affect ACTH- and CRF levels in plasma, the 
HPA axis was not altered in the model. Although the 
diversity of the dominating taxa of the gut microbiota 
was unaffected by buserelin, assessed by calculation 
of richness and diversity, the amount of Enterobacte-
riaceae was lowered in colonic tissue. Intestinal perme-
ability was not affected during basal conditions in either 
group, but the carbachol-induced increase of ileum per-
meability in controls was totally attenuated in busere-
lin-treated rats. Buserelin treatment did not affect stress 
behavior.
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The mechanisms behind the enteric neuronal cell loss 
can only be speculated on. Raised serum levels of estra-
diol after buserelin treatments, with secondary effects on 
vaginal smears and the uterine muscle layer [8], confirm 
that there are elevated levels of FSH- or LH secretion dur-
ing the dose regimen of the rat model [5]. Intermittent 
stimulation of LH in cell culture led to reduced survival 
of rat enteric neurons, whereas GnRH did not affect the 
neuronal survival [20]. The enteric neuronal loss in rat was 
most pronounced in colon, where also the relative number 
of enteric neurons IR to LH receptors was decreased after 
buserelin treatment [5]. As no inflammation was present in 
the bowel wall or in the circulation [5, 8], and the relative 
number of neurons IR to activated caspase-3 was increased 
prior to neuron reduction [5], apoptosis is assumed to be 
involved in the neuronal loss. For comparison, stimula-
tion of the LH receptors on human ovarian granulosa cells 
leads to increased apoptosis. The mechanisms involved 
may be mediated through cAMP, since cAMP is able to 
induce apoptosis in a variety of cell types, and its concen-
tration was increased after receptor stimulation [21]. In 
analogy, a down-regulation of LH receptors is accompa-
nied by decreased apoptosis [22]. Taking into considera-
tion all studies on enteric neuropathy and GnRH in man 
and rat, the buserelin-induced GI damage is postulated to 
be a degenerative and/or inflammatory enteric neuropathy 
driven by apoptosis; other pathological changes appear to 
be secondary to the neuropathy [2, 3, 5, 8, 23].
Fig. 4 The colonic microbiota was analyzed with next generation sequencing using the ion torrent platform. Firmicutes and Bacteroidetes were 
the two most dominant phyla in both controls (C) and buserelin (B)-treated rats. There were no significant differences between the C and B group 
regarding the relative abundance of any phyla or families (a). PCR-quantified amounts of selected bacterial families in tissue from ileum (b) and 
colon (c) of controls and buserelin-treated rats. The amounts of 16S rRNA gene copies from total bacteria and the C. leptum group were not statisti-
cally different between the C and B group in neither ileum nor colon. The amount of 16S rRNA gene copies from Enterobacteriaceae was significantly 
lower in tissue from colon (p = 0.020), but not ileum, in buserelin-treated rats compared with control rats. Samples under the detection limit were 
set to the highest possible detection limit. C = 7 rats and B = 11 rats. Results are presented as medians and interquartile ranges and were analyzed 
by the Mann–Whitney U-test. Statistical significance is indicated by *p < 0.05
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Adult neurons require ability to adapt, referred to as 
plasticity, to maintain their primary functions when 
exposed to pathophysiological situations. When sev-
eral neurotransmitters were studied, all were equally 
distributed in buserelin-treated rats and controls [8]. 
A reduced number of neurons along the GI tract would 
hypothetically lead to GI dysfunction. However, GI tran-
sit time, galactose absorption, and body weight were un-
affected, and the only significant functional change after 
buserelin treatment was an increased fecal fat content, 
suggesting fat maldigestion [8]. A huge reserve capac-
ity of ENS was suggested in the former study with pre-
served gut function after enteric neuronal loss of up 
to 50 % [8], and is confirmed in the present study. CRF 
receptor 1 is described on myenteric neurons in rat and 
man [14, 15, 17], and CRF increases both secretion and 
motor activity of the GI tract [10, 17]. Thus, the present 
finding of relative increase in CRF-IR neurons in colon, 
the only affected neurotransmitter observed [8], could 
theoretically counteract a reduced GI function. Bacterial 
overgrowth is often related to anatomical or motility dis-
turbances of the GI tract, but is a late sign of dysfunction 
[24]. Our results of unaffected bacterial amount or diver-
sity, and intact total GI transit time [8], indicate that the 
motility patterns are well preserved with only half of its 
neurons intact. The reduced level of Enterobacteriaceae 
in colon may be the first sign of disturbed balance in 
enteric neurons and CRF immunoreactivity, alterations 
Fig. 5 Intestinal permeability studied in ileum of controls (C, left panel) and buserelin (B, right panel)-treated rats. Buserelin treatment did not affect 
baseline permeability in the ileum. Carbachol treatment of ileum in controls significantly enhanced the permeability of d-(1-14C)-mannitol (2.9 kBq/
mL), fluorescein isothiocyanate (FITC)-dextran (FD4) (1 mg/mL), and at 120 min also bovine serum albumin (BSA) (25 mg/mL), compared with the 
untreated ileum. Carbachol treatment (10 mM) failed to enhance the permeability of ileum from buserelin-treated rats. C = 7 rats and B = 11 rats. 
Results are presented as medians and interquartile ranges and were analyzed by the Mann–Whitney U-test. Statistical significance is indicated by 
*p < 0.05 and **p < 0.01
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which were most pronounced in colon. The Enterobac-
teriaceae family is associated with inflammation [25] as 
is also true for CRF [14]. The inflammatory process in 
ulcerative colitis is supposed to be modulated by periph-
eral CRF receptors [16]. The expression of TLR-4 on 
epithelial cells was increased by CRF receptor stimula-
tion in vitro and after sham stress, which decreased the 
established tolerance of the epithelial barrier from Gram 
negative bacteria and their products, e.g. LPS [26]. CRF 
receptors have also been found in Escherichia coli, which 
belongs to the Enterobacteriaceae family [27]. Hypotheti-
cally, the decrease of these bacteria in colon may be a 
protection mechanism due to increased CRF levels, to 
counteract effects by pro-inflammatory factors, and to 
prevent an inflammatory response and retain intact intes-
tinal permeability [16, 19, 26]. Causes or consequences of 
modifications in microbiota must be further studied in 
prospective studies.
Nitric oxide and, in particular VIP, have been estab-
lished to induce intestinal relaxation and secretion and to 
take part in neuronal survival [28, 29]. As up-regulation 
of VIP is seen in several pathophysiological situations, 
enteric neurons with the ability to increase their VIP 
expression have been suggested to be better protected 
against neuronal injuries [30]. In the present study where 
the rats were euthanized 2 weeks after the fourth treat-
ment session, no increases of relative numbers of NOS- 
or VIP-IR neurons were found, as in the former study 
where the rats were euthanized immediately afterwards 
[6]. The neuronal tissue damage might have subsided 
2 weeks later. The increased percentage of NOS- and VIP 
containing neurons also IR to CRF in the present study 
could possibly hamper the protective effect of NOS and 
VIP, since CRF in previous studies has been shown to 
counteract the protective effect of VIP [19]. In this con-
text, it may be noted that no direct association between 
intestinal CRF levels and gut dysfunction in intensive 
care unit patients was found [31].
Cholinergic stimulation by carbachol mimics stimu-
lation during a meal and has been shown to increase 
the permeability in rat epithelium [17], in accordance 
to our findings of increased ileum uptake of mannitol, 
FITC-dextran, and BSA in controls. As nerve-mast cell 
interactions are important in the rat barrier function 
[17], the inability of buserelin-treated rats to respond to 
carbachol might reflect the reduced neuronal number 
in ileum. Other components also may be involved. In 
jejunal submucosal tissues from pig, the barrier func-
tion was regulated by muscarinic receptors on epithelial 
cells, independently of ENS [32]. Whether the present 
functional loss observed is due to lack of submucosal or 
Fig. 6 In the elevated plus maze test (EPMT), no differences were detected in the total numbers of entries and numbers of entries into open arms 
or closed arms (a) in the buserelin-treated rats (B) compared with controls (C). Neither did the time spent in closed arms, open arms or in the center 
of the platform differ between the two groups (b). C = 8 rats and B = 11 rats. Results are presented as individual values and medians (a) or as medi-
ans (b) and were analyzed by the Mann–Whitney U-test
Fig. 7 Behaviors are presented in the forced swimming test (FST) as 
the time of struggling, swimming or floating during a 10-min session. 
No differences could be found in buserelin-treated rats (B) compared 
with controls (C). C = 8 rats and B = 11 rats. Results are presented as 
individual values and medians and were analyzed by the Mann–Whit-
ney U-test
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myenteric neurons, or both, remains unclear as we used 
un-separated, whole-wall mounts in the Ussing chamber 
studies.
There is a well-described interaction between CRF, 
mast cells, and enteric nerves in rodents [33]. In experi-
mental studies, CRF receptor 1 situated on mast cells 
has been suggested as at least partly responsible for the 
increase of mucus secretion, para- and transcellular per-
meability, and short-circuit currents induced by acute 
and chronic stress [10, 17, 33]. The effects are abolished 
in mast cell deficient rodents or blocked by CRF receptor 
1 antagonists [10]. As the percentages of CRF-IR neurons 
in ileum in the present study were equal in both groups, 
CRF was not involved in the carbachol-induced perme-
ability. A concomitant inflammation with increased num-
ber of mast cells, which was not seen in our rat model 
[5], could theoretically have reinforced the effects of a 
reduced number of enteric neurons.
In man, high intestinal integrity is important for 
health, and enhanced intestinal permeability influences 
the development of several diseases, e.g. irritable bowel 
syndrome (IBS) and depression [34]. Visceral hypersen-
sitivity is characteristic for patients with IBS, and stress 
is shown to exacerbate IBS symptoms [9]. This visceral 
sensitivity has been supposed to be mediated by brain 
CRF signaling, but more recent research suggest an equal 
contribution of the peripheral CRF signaling [10, 14]. 
Both increased permeability and visceral hypersensitiv-
ity seem to be mediated via CRF stimulation of mast cells 
[35, 36], which are found in close proximity to colonic 
neurons in IBS patients [37]. An exaggeration of the HPA 
axis has been shown in IBS patients, resulting in hyper-
responsiveness to CRF injections with enhanced colonic 
motility [38]. The microbiota composition affects the 
barrier function, and probiotic treatment attenuated the 
HPA axis to stress and blocked the stress-induced hyper-
permeability [39]. Taken together, although IBS-like 
symptoms sometimes appear after GnRH treatment [7], 
our rat model does not represent an IBS model since nei-
ther the gut microbiota, mast cell account [5], basal intes-
tinal permeability or HPA axis were influenced. Clinical 
examinations during stimulation by carbachol could be 
useful methods to differ between IBS and enteric neurop-
athy. In conclusion, this and our former study [8] suggest 
that patients with diffuse GI complaints may have enteric 
neuropathy although no organic changes may be found in 
standardized clinical examinations.
The FST per se induces increased ACTH secretion as 
a response to swimming [40]. Local injection of CRF to 
the nucleus accumbens in rats during the EPMT and 
FST increased anxiety-like and depression-like behav-
iors [41]. In a rat model of gastric irritation with central 
elevated levels of CRF immunoreactivity and ACTH, the 
CRF-1 receptor antagonist antalarmin has been shown to 
reverse the depression-like behavior in FST [13]. These 
results suggest endogenous CRF as a key player in behav-
ior responses, and both peripheral and central mecha-
nisms may be involved. However, the stress behavior in 
the present study was not affected by the increased CRF 
immunoreactivity in colon.
Altered central processing, early life events, and cog-
nitive and psychosocial factors are considered necessary 
prerequisites to develop functional gastrointestinal bowel 
diseases (FGBD) with comorbidity of affective disorders 
[42]. Significant differences in the neural processing of 
pain between IBS patients and controls further underline 
the importance of central factors in the pathophysiology 
of visceral hypersensitivity [43], and moderate enteric 
disease per se may not influence the development of 
depression.
Future studies have to explore the mechanisms why the 
buserelin-induced effects with a relative increase of CRF 
immunoreactivity and lowered amount of Enterobac-
teriaceae are most pronounced in colon. The increased 
CRF immunoreactivity in submucosal neurons seems 
to be due to a protection in CRF-IR neurons to death, 
whereas the increased CRF immunoreactivity in myen-
teric ganglia seems to be due to de-novo CRF gene acti-
vation. Why CRF is affected differently compared with 
other subpopulations of neuropeptides has to be exam-
ined [8]. Also, the expression of CRF receptors would be 
of interest to examine, but the immunocytochemistry 
with available antibodies has failed so far.
Conclusion
A rat model of GnRH analog-induced enteric neuronal 
loss, without concomitant inflammation, has a well pre-
served gut function although it renders an increased 
relative number of CRF-IR enteric neurons, lowered 
levels of Enterobacteriaceae in colon, and an inability of 
ileum to respond to carbachol with increased perme-
ability. When several functions of the GI tract have been 
examined, the only significant GI dysfunctions meas-
ured are increased fecal fat content [8] and an inability 
of carbachol to increase ileum permeability. Both these 
dysfunctions reflect impaired small intestinal functions, 
and increased relative CRF immunoreactivity and low-
ered amount of Enterobacteriaceae were only identified 
in colon. Thus, GI dysfunction in buserelin-induced neu-




Female Sprague–Dawley rats (n  =  60, 7  weeks of age, 
170–180  g), purchased from Charles River, Sulzfeld, 
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Germany, were used. The rats were allowed to acclima-
tize to the climate- and light-controlled animal facility for 
at least 5 days prior to experimentation. Water and stand-
ard rat chow (4 % fat/g) (Lactamin R36, Stockholm, Swe-
den) were supplied at all times, except when withdrawn 
during experimental tests. The experimental design was 
approved by the Animal Ethics Committee, Lund and 
Malmö, Sweden (M350-12, date of approval 14.11.12). 
Animals were used in accordance with the European 
Communities Council Directive (2010/63/EU) and the 
Swedish Animal Welfare Act (SFS 1988:534).
Study design
Rats (n = 36) were given 20 μg of the GnRH analog buser-
elin (Suprefact® [1  mg/ml], Sanofi-Aventis, Bromma, 
Sweden) (dissolved in 0.2 ml saline) subcutaneously, once 
daily for 5  days, followed by 3  weeks of recovery, rep-
resenting one session of treatment (for details see Sand 
et al. [5]). All rats received four treatment sessions. The 
dosage and administration of buserelin are based on 
previous studies showing reliable physiological effects 
in terms of uterine hypertrophy, synchronization of the 
hormonal cycle, and elevated estradiol levels after four 
treatment sessions, without any adverse effects [5, 8]. 
Control rats (n = 24) received saline injections (0.2 ml). 
The rats were weighed prior to inclusion in the study, 
and weekly in the morning during the study, using elec-
tronic scales. As histological analyses in previous studies 
were performed immediately after the fourth treatment 
session, with very modest effects on GI structure except 
neuropathy and ganglioneuritis [5, 23], we wanted to per-
form the present analyses a few weeks later to get further 
information about the chronic course.
Two weeks after the fourth treatment session, 12 buser-
elin-treated and eight control rats (26 weeks of age) were 
anaesthetized with chloral hydrate (300  mg/kg) in the 
morning and thereafter euthanized through aorta punc-
ture. Blood was collected and plasma was analyzed for 
concentrations of ACTH and CRF. Tissue samples from 
the fundus, distal ileum, proximal colon, and uterus were 
collected and rinsed in saline before being fixed and pro-
cessed for cryo/paraffin sectioning. The total number 
of enteric neurons was assessed, as well as the relative 
numbers of neurons IR to CRF, NOS, and VIP. Tissue 
samples of ileum and colon were collected for analyses of 
intestinal microbiota and placed on dry ice directly after 
removal from the rat, and stored at −80 °C, before being 
analyzed by Terminal Restriction Fragment Length Poly-
morphism (T-RFLP), next generation sequencing, and 
quantitative polymerase chain reaction (qPCR).
Twelve buserelin-treated and eight control rats 
(26–28  weeks of age) were euthanized during a 2-week 
period, with start 10  days after the fourth treatment 
session, for examination of intestinal permeability in 
Ussing chambers.
Twelve buserelin-treated and eight control rats (27–
28 weeks of age) were examined by EPMT at day 10 and 
11, and by FST at day 17 and 18, after the fourth treat-
ment session, to assess anxiety-like behavior and depres-
sion-like activity, respectively, with ability for the rats to 
rest in-between.
Blood preparation and plasma analyses
Blood samples were collected in lithium heparin tubes (BD 
Microtainer, New Jersey, USA) through aorta puncture. 
Blood was centrifuged at 3000 rcf (1.12 × R × (RPM/1000)2) 
for 5 min and plasma was stored at −20 °C.
The levels of ACTH in plasma were analyzed in 
duplicate with a competitive inhibition enzyme-linked 
immunosorbent assay (ELISA) kit (CEA836Ra lot no 
L40505077, Cloud-Clone Corp., Nordic Diagnostica AB, 
Billdal, Sweden) according to the manufacturer’s manual. 
Standards and rat heparin plasma, diluted 1:2 in 0.01 M 
phosphate-buffered saline (PBS), pH 7.2, were incu-
bated in a plate which was pre-coated with a monoclo-
nal anti-ACTH antibody. The unbound conjugate was 
washed off and avidin-conjugated horseradish peroxidase 
(HRP) was added. The wells were incubated with 3,3′, 
5,5′-Tetramethylbenzidine (TMB) for HRP enzyme, and 
the product of the enzyme-substrate reaction formed a 
blue-colored complex. The reaction was stopped and the 
absorbance was measured at the optic density of 450 nm. 
The amount of bound HRP conjugate was reversed pro-
portional to the concentration of ACTH in the samples, 
and the ACTH concentration in each sample was inter-
polated from the standard curve.
CRF levels in plasma were analyzed with a commer-
cial ELISA kit (RSCYK131R lot no 2130719, Biovendor, 
Awakura, Fujinomiya-Shi Shizuoka, Japan) based on a 
sandwich enzyme immunoassay. The plate was coated 
with antibodies against mouse/rat CRF, and standards 
(0.0, 0.039, 0.078, 0.313, 0.625, and 1.25  ng/ml) and 
plasma (50 µl/well) were added in duplicate for the first 
step of immunoreaction. Second, a biotinylated rabbit 
anti-mouse/rat antibody was added to form a labeled 
antigen–antibody complex, and third, streptavidin-HRP 
was added. Substrate was then added to the wells and 
after a proper incubation time, the reaction was stopped 
with a sulfuric acid solution. The color change was meas-
ured at 450 nm and the sample concentration was inter-
polated from the standard curve.
Morphometric and neuronal survival experiments
Tissue preparation
A total of 20 female rats (12 buserelin-treated and eight 
controls) were used. The fundus/corpus region of the 
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stomach, ileum (with start 8  cm proximally to cecum 
and continuing in proximal direction), colon (with start 
2  cm distally to cecum and continuing in distal direc-
tion), and uteri were opened and flattened on filter paper. 
One portion of each gut segment was fixed in Stefanini’s 
fixative (a mixture of 2 % formaldehyde and 0.2 % picric 
acid in phosphate buffer, pH 7.2) for 22  h at 4  °C. The 
other portion of gut segments and uteri were fixed in 4 % 
paraformaldehyde in 0.1 M phosphate buffer for 22 h at 
4  °C. Stefanini-fixed, whole-wall specimens were rinsed 
in Tyrode’s solution containing 10 % sucrose three times 
before being oriented and mounted for cross- and longi-
tudinal sectioning in Tissue-Tek (Sakura, Histolab, Göte-
borg, Sweden), frozen on dry ice, and sectioned (10 μm). 
Paraformaldehyde-fixed, whole-wall specimens were 
dehydrated in ethanol, cleared in xylene, oriented for 
cross- and longitudinal sectioning, embedded in paraffin, 
and sectioned (5 µm). Sections were processed for immu-
nocytochemistry and histochemistry.
Histochemistry
Automated measurements of wall layer thickness were 
performed on scanned, deparaffinized, hydrated, and 
hematoxylin-eosin-stained paraffin sections from the 
uterus by using a computerized, image analyzing system 
(Imagescope, Aperio ScanScope GL SS5082, Vista, CA, 
USA). The myometrial thickness was measured using a 
binary cursor; mean values of 6–10 representative meas-
urements were calculated from each rat.
Immunocytochemistry
Neuronal survival and enteric neurons IR to CRF (fun-
dus, distal ileum, and proximal colon), NOS (proxi-
mal colon), and VIP (proximal colon) were studied as 
described in detail previously [5, 15]. NOS and VIP were 
only analyzed in colon, since the previous study showed 
most prominent effects on NOS- and VIP immunore-
activity in colon [5]. Briefly, to study neuronal survival, 
monoclonal mouse antibodies against the biotinylated 
human neural protein (HuC/D; dilution 1:400; code no 
A-2127, Life Technologies, Stockholm, Sweden) were 
used as a general neuronal marker and visualized with a 
VECTASTAIN ABC kit containing HRP and 3,3′-diam-
inobenzidine tetrahydrochloride (DAB) (Vector Labora-
tories, Inc., CA, USA). The relative number of CRF-IR 
neurons was examined by CRF antibodies raised in rab-
bit (dilution 1:1600–1:3200; code no C-5348, Sigma-
Aldrich, St Louis, MO, USA) in combination with 
antibodies against HuC/D visualized with a mixture of 
DyLight TM 488-conjugated goat anti-mouse IgG serum 
and Alexa Fluor TM 594-conjugated donkey anti-rabbit 
IgG serum. The relative numbers of CRF-IR neurons 
also IR to NOS or VIP were studied by CRF antibody in 
combination with NOS antibodies raised in sheep (dilu-
tion 1:3200; code no 1529, Chemicon international, Bill-
erica, MA, USA) or monoclonal VIP antibodies raised in 
mouse (dilution 1:5000; code no 9535-0504, Biogenesis 
Ltd, Poole, UK). These two combinations were visual-
ized by exposure to DyLight TM 488-conjugated donkey 
anti-goat IgG serum and Alexa Fluor TM 594-conjugated 
donkey anti-rabbit IgG serum (dilution 1:1000) or to 
DyLight TM 488-conjugated goat anti-mouse IgG serum 
and Alexa Fluor TM 594-conjugated donkey anti-rabbit 
IgG serum (dilution 1:1000), respectively. All secondary 
antibodies were from Jackson ImmunoResearch Labora-
tories, Inc., Novakemi AB, Handen, Sweden. Synthetic 
antigens for testing the specificity of antibodies against 
HuC/D are not commercially available. Thus, omission of 
the primary antibodies was used as controls. Regarding 
the specificity of NOS and VIP, absorption controls were 
performed by adding an excess amount of antigen (10–
100 µg of synthetic peptide diluted in antiserum) before 
exposure.
The number of HuC/D neurons in colon was counted 
in scanned, cross- and longitudinally cut, whole-wall sec-
tions and evaluated in a total length of at least 30 mm, cut 
at 6–9 different depths per region and rat. Neuronal sur-
vival is expressed as numbers of HuC/D-IR submucosal 
or myenteric neurons per mm region length. At least 150 
submucosal and 250 myenteric HuC/D-IR neurons were 
estimated for simultaneous co-localization of CRF from 
each region and rat. At least 30 mm section lengths were 
analyzed for neuron immunoreactivity to NOS and VIP 
in addition to CRF. The results on the subpopulations are 
expressed as the percentage of HuC/D-, NOS- or VIP-IR 
neurons also IR to CRF.
Microbial analyses
DNA extraction
Whole-wall tissue samples from 20 female rats (12 buser-
elin-treated and eight controls) were used, since the bac-
teria content in the mucosa is more representative for the 
microbiota than feces. DNA from distal ileum and proxi-
mal colonic tissue (0.03–0.06 g) was isolated and purified 
in EZ1 Advanced XL (EZ1 DNA Tissue kit and Bacteria 
card, Qiagen, Hilden, Germany). Samples were incu-
bated with 380 µl Buffer G2 and 30 µl Proteinase K (Qia-
gen) and 12 glass beads (2 mm in diameter) at 56 °C until 
totally lysed (for approximately 4  h). The lysates were 
shaken at 4 °C for 45 min to further disintegrate the bac-
terial cell walls. The lysates were spin down shortly and 
200 µl was used for extraction in the EZ1 Advanced XL.
Microbial diversity
To assess the microbial diversity, T-RFLP was applied. 
The 16S rRNA genes were amplified with the universal 
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forward primer FAM-ENV1 (5′-AGA GTT TGA TII 
TGG CTC AG-3′), fluorescently labeled with carboxy-
fluorescein (6-FAM) at the 5′ end, and the reverse 
primer ENV2 (5′-CGG ITA CCT TGT TAC GAC TT-3′) 
(I =  inosine), which anneal by 8–27 base pairs (bp) and 
1511–1492  bp, respectively. The PCR reaction mixture 
contained 0.4  µM FAM-ENV1 primer, 0.2  µM ENV2 
primer (Eurofins MWG, Ebersberg, Germany), 0.2 mM of 
each deoxyribonucleotide triphosphate (Qiagen), 2.5  µl 
of 10× TopTaq PCR reaction buffer (containing 15 mM 
MgCl2) (Qiagen), 0.625  units TopTaq DNA Polymer-
ase (Qiagen), 2.5 µl of 10× CoralLoad (Qiagen), and 
2.5–6  µl of template, in a final volume of 25  µl. Ampli-
fication was made in an Eppendorf Mastercycler (Ham-
burg, Germany) using the following program: one cycle 
at 94 °C for 3 min, followed by 30 cycles; denaturation at 
94 °C for 1 min, annealing at 50 °C for 45 s, and extension 
72 °C for 2 min, with an additional extension at 72 °C for 
10 min in the end. PCR products were verified on 1.5 % 
agarose gel with GelRed nucleic acid gel stain (Biotium, 
Hayward, CA, USA). Products from three PCR reactions 
were pooled, purified, and concentrated by MinElute 
PCR Purification Kit (Qiagen) according to the manufac-
turer’s protocol. The DNA was eluted in 20 µl of RNAse-
free water (Qiagen) and the concentration was measured 
by NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies, Wilmington, DE, USA) using 1 µl purified 
PCR product. T-RFLP analysis was performed with MspI 
and electropherograms were analyzed with GeneMap-
per® version 4.1 (Applied Biosystems, Foster city, CA, 
USA) as described elsewhere [44]. Thresholds for internal 
standard and terminal restriction fragments (T-RFs) were 
set to 18 and 40 fluorescence units, respectively.
Next generation sequencing
Partial 16S rRNA gene sequences of the V3 region were 
amplified from extracted DNA of rat colon using Phu-
sion High-Fidelity DNA Polymerase (F-530S, Thermo 
Scientific, MA, USA). For each community a different 
forward primer, with a 10–12  bp unique barcode, was 
used to identify the different samples. Furthermore, the 
forward primers contained the A-adapter and the univer-
sal reverse primer 581R included the trP1-adapter, both 
needed for Ion Torrent sequencing. The complete list of 
primers used in this study is reported in Additional file 3: 
Table S1. The PCR conditions used were 98  °C for 30 s, 
followed by 27 cycles; denaturation at 98 °C for 15 s and 
annealing at 72 °C for 30 s followed by extension at 72 °C 
for 5 min, and then cooled to 4  °C. PCR products were 
purified by electrophoretic separation on a 1.5 % agarose 
gel and the use of MinElute Gel extraction kit (Qiagen). 
DNA concentrations were determined with Qubit® high 
sensitivity assay (Life Technologies) and the amount 
was adjusted so an equimolar mixture of all the different 
libraries was obtained. Sequencing was performed on a 
318 chip using the Ion OneTouch™ 200 Template Kit v2 
DL (Life Technologies). After sequencing, the individual 
sequence reads were processed in the CLC BIO genomic 
workbench version 6 (CLC Bio, Aarhus, Denmark) to 
remove low quality and polyclonal sequences. Approxi-
mately 40,300 good quality reads of 110–180  bp were 
obtained from each sample and further processed in the 
Ribosomal Database Project. The domain Bacteria was 
used as reference when calculating the relative abun-
dance of phyla and families.
Quantitative PCR
The total amount of bacteria and the bacterial abundance 
of Clostridium leptum, Enterobacteriaceae, and Bacte-
roides fragilis were estimated in tissue from ileum and 
colon, using separate quantitative PCR assays according to 
Karlsson et al. [45]. Primers used for the qPCR assays have 
been published previously [46–48]. The detection limit for 
C. leptum and Enterobacteriaceae was 102 gene copies/
reactions, whereas the limit for total bacteria and B. fra-
gilis was 103 gene copies/reactions. For standard curves, 
tenfold dilution series of the target DNA were made in 
EB buffer (Qiagen). Number of bacteria was expressed as 
log10 16S rRNA gene copies/g ileum or colon tissue.
Calculations
Microbial diversity was estimated by calculation of rich-
ness (number of T-RFs) and Shannon and Simpson diver-
sity indices as described by Karlsson et al. [45], with the 
exception that T-RFs within 40–580 bp were included in 
the T-RFLP profile analysis and calculation. The diversity 
indices take into accountability both richness and even-
ness when considering the relative abundance of bacterial 
groups. Both indices are commonly used to assess micro-
bial diversity [49]. Samples under the detection limit in 
the qPCR runs were set to the highest possible detection 
limit for statistical analysis.
Ussing chamber experiments
Procedure
A total of 20 female rats (280–320 g; 12 buserelin-treated 
and eight controls) were anaesthetized with chloral 
hydrate (300  mg/kg) in the morning. The distal half of 
the small intestine and the proximal half of the colon 
was dissected, rinsed, and immersed in room-tempered 
modified Krebs buffer (0.1 M NaCl/3 mM CaCl2/5.5 mM 
KCl/14 mM KH2PO4/29 mM NaHCO3/5.7 mM Na-pyru-
vate/7 mM Na-fumarate/5.7 mM Na-glutamate/13.4 mM 
glucose/pH 7.4), oxygenated with carbogen (95/5  %, 
O2/CO2). The intestine was then cut in 3  cm sections, 
opened along the anti-mesenteric border, and the whole 
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tissue was mounted in the Ussing diffusion chambers 
(exposed intestinal area of 1.78 cm2) in accordance with 
previous description [50, 51]. Each half-cell of the Ussing 
chambers were filled with 5  ml of Krebs buffer, kept at 
37  °C, and connected to carbogen supply. All intestinal 
segments were mounted in the chambers within 30 min 
after dissection and were considered viable for 2 h [52].
At start of the experiment, the buffer was exchanged 
to a fresh Krebs buffer in the serosal half-cell, and to a 
marker-containing buffer in the mucosal half-cell. This 
consisted of fresh Krebs buffer, in which glucose was 
exchanged with mannitol (13.4  mM), containing the 
marker molecules d-(1-14C)-mannitol (182  Da, cham-
ber concentration: 2.9  kBq/mL, specific activity of the 
isotope: 2.035  GBq/mmol; PerkinElmer, Massachusetts, 
USA), FITC-dextran (4 000 Da, chamber concentration: 
1  mg/mL; TdB Consultancy AB, Uppsala, Sweden), and 
BSA (66 000  Da, chamber concentration: 25  mg/mL; 
A-4503, Sigma-Aldrich). One section of ileum and colon 
were exposed to the marker solution, and in addition, 
one part of the ileum was supplemented with the acetyl-
choline receptor agonist carbamoylcholine, also called 
carbachol (Carbachol®, chamber concentration: 10 mM, 
Sigma-Aldrich) in the serosal buffer. Serosal samples of 
1  ml were collected every 20  min during 120  min and 
replaced with the same volume by fresh buffer.
Analyses
The amount of radio-labeled mannitol in the serosal sam-
ples was measured in a beta counter (Scint TriCarb Liq-
uid Scintillation Analyzer 2100TR, PerkinElmer), after 
mixing 0.5 ml of the serosal sample with 5 ml liquid scin-
tillation cocktail (Optiphase ‘Highsafe’ 2, Perkin Elmer). 
FITC-dextran was quantified by fluorescence spectro-
photometry (CytoFlour™ 2300, Millipore Corp., Bedford, 
MA, USA) at an excitation wavelength of 480 nm and an 
emission wavelength of 520 nm. FITC-dextran dissolved 
in modified Krebs buffer was used as a standard. Quan-
tification of BSA was carried out by electro immunoas-
say in agarose gel [53] with an antisera specific to BSA 
(B-1520 Rabbit Anti-Bovine Albumin, Sigma-Aldrich), 
using purified BSA (A-7639, Sigma-Aldrich) as the 
standard.
Calculations
The passage of d-(1-14C)-mannitol, FITC-dextran and 
BSA over the intestinal segments was determined as the 
percentage passage from mucosal to serosal half-cell at 
indicated time-points.
Stress behavior tests
A total of 20 female rats (12 buserelin-treated and eight 
controls) were analyzed by stress behavior tests.
Elevated plus maze test
The EPMT has been developed to assess anxiety-like 
behavior [54]. The apparatus consisted of two open arms 
(50 × 10 cm2) surrounded by a 1-cm-high Plexiglass and 
two closed arms (50 × 10 × 38 cm3) that emerge from a 
central platform. The apparatus was made from dark grey 
PVC and the arms were elevated 73 cm above the floor. 
A white incandescent bulb provided a light intensity of 
300 lux over the open arms and of 20 lux over the closed 
arms. At the beginning of each trial, the rat was placed 
on the central platform facing an open arm. The floor of 
the maze was cleaned with 10 % ethanol before each trial. 
The rat behavior was videotaped over 10 min (divided in 
one initial and one latest 5-min session), and a trained 
observer blinded to the treatment groups scored the 
parameters from the videotape. The behavioral param-
eters scored were: the numbers of total entries; the num-
bers of entries into closed and open arms (an entry was 
counted when both forepaws were placed on the respec-
tive arm); the time spent in the closed arms, open arms, 
and in the center platform; and the numbers of entries 
into the outer part of the open arms and the time spent 
their. The numbers of open arm head dips (standing on 
the open arm, leaning the head over the Plexiglass edge) 
and protected arm head dips (standing with the body in 
the protected arms, leaning the head over the Plexiglass 
edge) were investigated.
Forced swimming test
The procedure of FST was a modification of that 
described by Porsolt et  al. [55]. Animals were placed 
in individual glass cylinders (diameter: 25  cm, height: 
60  cm) containing water (height: 40  cm, temperature: 
25 °C). One 10-min session was conducted. The duration 
in seconds of struggling, swimming, and floating were 
manually measured during the initial and latest 5-min 
period of the test session by an experimenter unaware 
of the treatment groups. The numbers of diving were 
recorded. Struggling was defined as strong movement of 
all four limbs with the front paws breaking the water sur-
face or scratching the glass cylinder wall. Swimming was 
defined as movements of 2–4 limbs, swimming around in 
the tank or diving. Floating occurred when rats remained 
immobile with only occasional slight movements to keep 
the body balance and the nose above the water.
Statistical analyses
Results are presented as median (interquartile range 
[IQR]), except for weight which is expressed as 
mean  ±  standard error of the mean (SEM). Statistical 
analyses were performed in GraphPad Prism  6 (Graph-
Pad Software, Inc., La Jolla, CA, USA) using the Student’s 
t test for the normally distributed weight variable and the 
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Mann–Whitney U-test for the other variables due to the 
low number of animals. P < 0.05 was considered statisti-
cally significant.
Abbreviations
ACTH: adrenocorticotropic hormone; BSA: bovine serum albumine; CRF: cor-
ticotropin-releasing factor; ENS: enteric nervous system; EPMT: elevated plus 
maze test; FITC: fluorescein isothiocyanate; FSH: follicle-stimulating hormone; 
FST: forced swimming test; GnRH: gonadotropin-releasing hormone; HPA: 
hypothalamic–pituitary–adrenal; HuC/D: human neuronal protein; IBS: irritable 
bowel syndrome; IR: immunoreactive; LH: luteinizing hormone; MG: myenteric 
ganglia; NOS: nitric oxide synthase; SG: Submucosal ganglia; T-RFLP: terminal 
restriction fragment length polymorphism; VIP: vasoactive intestinal peptide.
Authors’ contributions
All authors made substantial contributions to the conception and design of 
the study, participated in the interpretation of the statistical analyses, and 
participated in revising the manuscript critically for important intellectual con-
tent. ES performed the animal trials, performed most laboratory experiments, 
and made the statistical calculations. CL performed all the microbiota analyses 
and calculations. BR performed several laboratory analyses. BW, ES, and LL 
performed chamber experiments and analyses. ES and Emil E performed the 
EPMT and FST. BO and ES wrote the manuscript and BO, BW, EE, ES, CL and GM 
financed the study. All authors have read and approved the final manuscript.
Author details
1 Division of Internal Medicine, Department of Clinical Sciences, Skåne Uni-
versity Hospital, Lund University, Inga Marie Nilssons street 32, 205 02 Malmö, 
Sweden. 2 Neurogastroenterology Unit, Department of Experimental Medical 
Science, BMC B11, Lund University, 221 84 Lund, Sweden. 3 Department 
of Food Technology, Engineering and Nutrition, Lund University, 22100 Lund, 
Sweden. 4 Department of Biology, Functional Biology, Lund University, 221 
84 Lund, Sweden. 5 Department of Clinical Neuroscience and Rehabilitation, 
University of Gothenburg, 405 30 Gothenburg, Sweden. 
Acknowledgements
The study was funded by the Swedish Society for Medical Research, The Royal 
Physiographic Society in Lund, Bengt Ihre’s and A Påhlsson´s Foundations, 
Gustaf V and Queen Victorias Free Mason’s Foundation and Lund Medical 
Faculty. We thank Anna Themner-Persson for valuable technical assistance and 
Martin Ian Bahl at Denmark Technical University for valuable help regarding 
next generation sequencing.
Competing interests
The authors declare that they have no financial or competing interests to 
disclosure.
Additional files
Additional file 1: Figure S1. Numbers of neurons in submucosal (SG) 
and myenteric ganglia (MG) per mm length in colon from rats treated 
with four sessions of saline (controls, C) or buserelin (B). Rats were 
euthanized 2 weeks after the fourth treatment session. Neuronal counting 
was performed on longitudinally cut, whole-wall sections. Rats subjected 
to four sessions of buserelin treatment showed an equal number of 
submucosal neurons immunoreactive to corticotropin-releasing factor 
(CRF) in colon compared with controls. The number of myenteric neurons 
immunoreactive to CRF in colon was increased after buserelin treatment 
compared with controls (p < 0.05). C = 6 rats and B = 6 rats. Results are 
presented as individual values and medians and were analyzed by the 
Mann–Whitney U-test. Statistical significance is indicated by * = p < 0.05.
Additional file 2: Table S2. Microbial diversity in rat tissue from ileum 
and colon.
Additional file 3: Table S1. List of primers used in the present study.
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